JPM Global Healthcare C (acc) USD

Performance History31/03/2024
Growth of 1,000 (EUR)
JPM Global Healthcare C (acc) USD
Fund14.120.4-2.70.010.3
+/-Cat2.93.77.10.83.6
+/-Idx--5.6-2.80.20.8
 
Key Stats
NAV
25/04/2024
 USD 603.23
Day Change -0.88%
Morningstar Category™ Sector Equity Healthcare
ISIN LU0432979887
Fund Size (Mil)
25/04/2024
 USD 4142.26
Share Class Size (Mil)
25/04/2024
 USD 375.50
Max Initial Charge -
Ongoing Charge
06/12/2023
  1.00%
Investment Objective: JPM Global Healthcare C (acc) USD
To achieve a return by investing primarily in pharmaceutical, biotechnology, healthcare services, medical technology and life sciences companies ("Healthcare Companies"), globally.
Returns
Trailing Returns (EUR)25/04/2024
YTD6.19
3 Years Annualised5.51
5 Years Annualised10.62
10 Years Annualised10.89
12 Month Yield 0.00
Management
Manager Name
Start Date
Holly Fleiss
09/06/2022
Dominic Valder
05/10/2022
Click here to see others
Inception Date
02/10/2009
Advertisement
Benchmarks
Fund BenchmarkMorningstar Benchmark
MSCI World/Health Care NR USDMorningstar Gbl Health TME NR USD
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNot Specific
GrowthYes
IncomeNot Specific
HedgingNot Specific
OtherNot Specific
Portfolio Profile for  JPM Global Healthcare C (acc) USD31/03/2024
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stocks99.060.0099.06
Bonds0.020.000.02
Cash1.380.460.92
Other0.000.000.00
Top 5 Regions%
United States79.38
Europe - ex Euro9.89
United Kingdom6.17
Eurozone3.01
Japan1.54
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
Eli Lilly and CoHealthcareHealthcare9.01
UnitedHealth Group IncHealthcareHealthcare7.66
Novo Nordisk A/S Class BHealthcareHealthcare5.96
AbbVie IncHealthcareHealthcare5.17
Regeneron Pharmaceuticals IncHealthcareHealthcare4.54
JPM Global Healthcare C (acc) USD

Related

This fund has performance data calculated prior to the inception date of the fund. This is based upon a simulated/extended track record and is in accordance with Morningstar’s Extended Performance Methodology paper. To find out more about this, click here.
In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)
© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookie Settings        Disclosures